Psyched Wellness Announces Inclusion in AdvisorShares Psychedelics Exchange Traded Fund (ETF)

Toronto, Ontario, September 22, 2021 – Psyched Wellness Ltd. (CSE:PSYC, OTCQB:PSYCF, FRANKFURT:5U9) (the “Company” or “Psyched”) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce it has been included in the new AdvisorShares Psychedelics Exchange Traded Fund (ETF).

Listed on the NYSE Arca under the ticker symbol (NYSE: ‘PSIL’), the ETF currently includes 23 psychedelics companies and actively manages investments in the emerging psychedelic drugs sector. The Fund offers exposure to those biotechnology, pharmaceutical and life sciences companies that AdvisorShares sees as leading the psychedelics industry.

Jeffrey Stevens, CEO of Psyched, said: “Psyched’s inclusion in the AdvisorShares Psychedelics Exchange Traded Fund acknowledges the important research and product development the Company is doing on its proprietary extract of Amanita Muscaria, AME-1. We believe AME-1 has the power to help people achieve stress relief, relaxation and restful sleep. We are grateful that the ongoing work at Psyched has been recognized by AdvisorShares and we are among the leaders in the psychedelics industry.”

You can find additional details on the AdvisorShares Psychedelics ETF here.